Elsulfavirine - Viriom
Alternative Names: Elpida; elpivirine; R1206; RO 4970335; RO 5011500; VM 1500Latest Information Update: 28 May 2023
At a glance
- Originator Roche
- Developer Viriom
- Class Acetamides; Antiretrovirals; Antivirals; Nitriles; Small molecules; Sulfones
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed HIV infections
- Phase II COVID 2019 infections
Most Recent Events
- 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in China (PO, Tablet)
- 13 Jul 2022 Viriom completes a phase I trial for HIV-I infections (In volunteers) in USA (NCT05165550)
- 16 Aug 2021 Viriom completes a phase I pharmacokinetics trial in healthy volunteers in Russia (NCT05148754)